UBS lifts Teva stock price target to $30, maintains Buy rating
UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...
Hosted on MSN48m
Sources: Maynilad hires banks for public listing
Maynilad Water Services has hired banks including Morgan Stanley and UBS to work on a more than $500-million initial public offering (IPO) in the Philippines, according to two sources with knowledge ...